MILWAUKEE, June 23, 2022 /PRNewswire/ -- Ademi LLP is investigating F-star FSTX for possible breaches of fiduciary duty and other violations of law in its transaction with invoX.
Click here to learn how to join the action: https://www.ademilaw.com/case/f-star-therapeutics-inc or call Guri Ademi toll-free at 866-264-3995. There is no cost or obligation to you.
Ademi LLP alleges F-star's financial outlook and prospects are excellent and yet F-star holders will receive only $7.12 per share. The acquisition values F-star at approximately $161 million. The transaction agreement unreasonably limits competing bids for F-star by imposing a significant penalty if F-star accepts a superior bid. F-star insiders will receive substantial benefits as part of change of control arrangements.
We are investigating the conduct of F-star's board of directors, and whether they are (i) fulfilling their fiduciary duties to all shareholders, and (ii) obtaining a fair and reasonable price for F-star.
If you own F-star common stock and wish to obtain additional information, please contact Guri Ademi either at gademi@ademilaw.com or toll-free: 866-264-3995, or https://www.ademilaw.com/case/f-star-therapeutics-inc.
We specialize in shareholder litigation involving buyouts, mergers, and individual shareholder rights throughout the country. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes.
Ademi LLP
Guri Ademi
Toll Free: (866) 264-3995
Fax: (414) 482-8001
SOURCE Ademi LLP
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
